BMY Forex-Nachrichten
I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study
Biotech company I-Mab (IMAB) announced Wednesday that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY).
RTTNews
|
vor 156 Tagen
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation
Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
RTTNews
|
vor 186 Tagen
Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers
Radiopharmaceutical company Perspective Therapeutics, Inc. (CATX) announced Tuesday a clinical trial collaboration agreement with Bristol Myers Squibb Co. (BMY) to evaluate the safety and tolerability of Perspective's targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb's nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.
RTTNews
|
vor 234 Tagen
Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update
While reporting financial results for the fourth quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2024.
RTTNews
|
vor 280 Tagen
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal
Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announced Tuesday a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
RTTNews
|
vor 318 Tagen
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash
Bristol-Myers Squibb Co. (BMY) and biopharmaceutical company Karuna Therapeutics, Inc. (KRTX) announced Friday that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
RTTNews
|
vor 322 Tagen
Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb
Biopharmaceutical company Avidity Biosciences, Inc. (RNA) announced Tuesday a global licensing and research collaboration with Bristol Myers Squibb (BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.
RTTNews
|
vor 346 Tagen
Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates
While reporting financial results for the third quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) lowered its adjusted earnings guidance for the full-year 2023, while maintaining annual revenue outlook.
RTTNews
|
vor 379 Tagen
Bristol-Myers Squibb Slashes FY23 Outlook As Q2 Results Miss Estimates
While reporting financial results for the second quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its adjusted earnings and revenue growth guidance for the full-year 2023, primarily due to lower than expected sales of Revlimid, and to a lesser extent, Pomalyst.
RTTNews
|
vor 470 Tagen
Bristol-Myers Squibb Affirms FY23 Outlook; Q1 Adj. EPS Tops Estimates
While reporting financial results for the first quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) affirmed its adjusted earnings and revenue growth guidance for the full-year 2023.
RTTNews
|
vor 561 Tagen
